Extended Endocrine Therapy Predictive Validation: Stockholm

Breast Cancer Index Identifies Early-Stage Estrogen Receptor–Positive Breast Cancer Patients at Risk for Early- and Late-Distant Recurrence

In this study, a linear model of Breast Cancer Index (BCI), an algorithmic gene expression–based signature was evaluated for its ability to predict both early (0–5 years) and late risk of distant recurrence in estrogen receptor–positive (ER⁺) lymph node–negative (LN⁻) breast cancer.¹